REFERENCES
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Mathers C. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
2. Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 2013;47:S2-6.
3. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-91.
4. Kew MC. Hepatocellular carcinoma: epidemiology and risk factors. J Hepatocell Carcinoma 2014;1:115-25.
5. Bréchot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 2004;127:S56-61.
6. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
7. Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol 2018;3:383-403.
8. Lim JK, Nguyen MH, Kim WR, Gish R, Perumalswami P, Jacobson IM. Prevalence of Chronic Hepatitis B Virus Infection in the United States. Am J Gastroenterol 2020;115:1429-38.
9. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335-52.
10. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264-73.e1.
11. Kuper H, Tzonou A, Kaklamani E, et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 2000;85:498-502.
12. El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Hepatology 2014;60:1767-75.
13. Coffin CS, Fung SK, Ma MM. Canadian Association for the Study of the Liver. Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol 2012;26:917-38.
14. Ashhab AA, Rodin H, Powell J, Debes JD. Impact of immigration in presentation and outcomes of hepatocellular carcinoma in the USA. Eur J Gastroenterol Hepatol 2019;31:24-28.
15. Ashhab AA, Rodin H, Powell J, Debes JD. Hepatocellular carcinoma diagnosis and surveillance: Socioeconomic factors don't seem to matter, unless you are an immigrant. J Hepatol 2017;67:648-9.
16. Ching LK, Gounder PP, Bulkow L, et al. Incidence of hepatocellular carcinoma according to hepatitis B virus genotype in Alaska Native people. Liver Int 2016;36:1507-15.
17. Hayashi S, Khan A, Simons BC, et al. An association between core mutations in hepatitis B virus genotype F1b and hepatocellular carcinoma in Alaskan native people. Hepatology 2019;69:19-33.
18. Kallwitz ER, Daviglus ML, Allison MA, et al. Prevalence of suspected nonalcoholic fatty liver disease in Hispanic/Latino individuals differs by heritage. Clin Gastroenterol Hepatol 2015;13:569-76.
19. Méndez-Sánchez N, Aguilar-Ramírez JR, Reyes A, et al. Etiology of liver cirrhosis in Mexico. Ann Hepatol 2004;3:30-3.
20. Arab JP, Dirchwolf M, Álvares-da-Silva MR, et al. Latin American Association for the Study of the Liver (ALEH) Practice Guidance for the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease. Ann Hepatol 2020;19:674-90.
21. Lizardi-Cervera J, Laparra DI, Chávez-Tapia NC, Ostos ME, Esquivel MU. Prevalence of NAFLD and metabolic syndrome in asymtomatics subjects. Rev Gastroenterol Mex 2006;71:453-9.
22. Goldberg DS, Taddei TH, Serper M, et al. Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis. Hepatology 2017;65:864-74.
23. Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol 2016;64:800-6.
24. Sharma SA, Kowgier M, Hansen BE, et al. Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. J Hepatol 2017:S0168-8278(17)32248.
25. Lin OS, Keeffe EB, Sanders GD, Owens DK, et al. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 2004;19:1159-72.
26. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68:723-50.
27. Singal AG, Pillai A, Pillai A. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014;11:e1001624.
28. World Health Organization. Global Cancer Observatory. Available from: https://gco.iarc.fr/. [Last accessed on 17 Mar 2021].
29. Fassio E, Díaz S, Santa C, et al. Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. Ann Hepatol 2010;9:63-9.
30. Carrilho FJ, Kikuchi L, Branco F, Goncalves CS, Mattos AA. Brazilian HCC Study Group. Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil. Clinics (Sao Paulo) 2010;65:1285-90.
31. Debes JD, Chan AJ, Chan AJ, et al. Hepatocellular carcinoma in South America: Evaluation of risk factors, demographics and therapy. Liver Int 2018;38:136-43.
32. Chan AJ, Balderramo D, Kikuchi L, et al. Early Age Hepatocellular Carcinoma Associated With Hepatitis B Infection in South America. Clin Gastroenterol Hepatol 2017;15:1631-2.
33. Marchio A, Cerapio JP, Ruiz E, et al. Early-onset liver cancer in South America associates with low hepatitis B virus DNA burden. Sci Rep 2018;8:12031.
34. Wong DK, Cheng SCY, Cheng SCY, et al. Among patients with undetectable hepatitis B surface antigen and hepatocellular carcinoma, a high proportion has integration of HBV DNA into hepatocyte DNA and no cirrhosis. Clin Gastroenterol Hepatol 2020;18:449-46.
35. Mattos Â, Mattos AA, Debes JD. Hepatocellular carcinoma: Unraveling the role of occult hepatitis B virus infection. Clin Gastroenterol Hepatol 2021;19:407-8.
36. Branco F, Mattos AA, Coral GP, et al. Occult hepatitis B virus infection in patients with chronic liver disease due to hepatitis C virus and hepatocellular carcinoma in Brazil. Arq Gastroenterol 2007;44:58-63.
37. Livingston SE, Simonetti JP, McMahon BJ, et al. Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis 2007;195:5-11.
38. Silva Souza ACD, Souza Marasca G, Kretzmann-Filho NA, et al. Identification of hepatitis B virus A1762T/G1764A double mutant strain in patients in Southern Brazil. Braz J Infect Dis 2017;21:525-9.
39. Wranke A, Pinheiro Borzacov LM, Parana R, et al. Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN). Liver Int 2018;38:842-50.
40. Marcon PDS, Tovo CV, Kliemann DA, Fisch P, de Mattos AA. Incidence of hepatocellular carcinoma in patients with chronic liver disease due to hepatitis B or C and coinfected with the human immunodeficiency virus: A retrospective cohort study. World J Gastroenterol 2018;24:613-22.
41. Ramírez-Soto MC, Ortega-Cáceres G, Cabezas C. . Trends in mortality burden of hepatocellular carcinoma, cirrhosis, and fulminant hepatitis before and after roll-out of the first pilot vaccination program against hepatitis B in Peru: An analysis of death certificate data. Vaccine 2017;35:3808-12.
42. Appel-da-Silva MC, Miozzo SA, Dossin IA, Tovo CV, Branco F, de Mattos AA. Incidence of hepatocellular carcinoma in outpatients with cirrhosis in Brazil: A 10-year retrospective cohort study. World J Gastroenterol 2016;22:10219-25.
43. Piñero F, Rubinstein F, Marciano S, et al. Surveillance for hepatocellular carcinoma: Does the place where ultrasound is performed impact its effectiveness? Dig Dis Sci 2019;64:718-28.
44. Alvarado-Mora MV, Pinho JR. Epidemiological update of hepatitis B, C and delta in Latin America. Antivir Ther 2013;18:429-33.
45. Méndez-Sánchez N, Ridruejo E, Alves de Mattos A, et al. Latin American Association for the Study of the Liver (LAASL) clinical practice guidelines: management of hepatocellular carcinoma. Ann Hepatol 2014;13 Suppl 1:S4-40.
46. Ferraz ML, Strauss E, Perez RM, et al. Brazilian Society of Hepatology and Brazilian Society of Infectious Diseases Guidelines for the Diagnosis and Treatment of Hepatitis B. Braz J Infect Dis 2020;24:434-51.
47. Piñero F, Tanno M, Aballay Soteras G, et al. Argentinean Association for the Study of Liver Diseases (A. A.E.E.H). Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. Ann Hepatol 2020;19:546-69.
48. Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: A meta-analysis. Gastroenterology 2018;154:1706-18.e1.
49. Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69:182-236.
50. Akinyemiju T, Abera S, Abera S et al. Global Burden of Disease Liver Cancer Collaboration. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: Results from the global burden of disease study 2015. JAMA Oncol 2017;3:1683-91.
51. Lai A, Sagnelli C, Presti AL, et al. What is changed in HBV molecular epidemiology in Italy? J Med Virol 2018;90:786-95.
52. Goutté N, Sogni P, Bendersky N, Barbare JC, Falissard B, Farges O. Geographical variations in incidence, management and survival of hepatocellular carcinoma in a Western country. J Hepatol 2017;66:537-44.
53. Allaire M, El Hajj W, Brichler S, et al. Prior surveillance and antiviral treatment improve the prognosis of HCC developed in HBV patients in the West. Clin Res Hepatol Gastroenterol 2020;45:101436.
54. Coppola N, Alessio L, Pisaturo M, et al. Hepatitis B virus infection in immigrant populations. World J Hepatol 2015;7:2955-61.
55. in cancer control. Innovations and research. Proceedings of the sixth annual meeting. A combined meeting of the Association of Community Cancer Centers/Association of American Cancer Institutes. Washington, D.C., March 15-16, 1988. Prog Clin Biol Res 1989;293:1-407.
56. Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370-98.
57. Papatheodoridis GV, Idilman R, Dalekos GN, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology 2017;66:1444-53.
58. Su TH, Hu TH, Chen CY, et al. C-TEAM study group and the Taiwan Liver Diseases Consortium. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int 2016;36:1755-64.
59. Sánchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodés J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002;123:1848-56.
60. Chen CJ, Yang HI, Iloeje UH. REVEAL-HBV Study Group. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009;49:S72-84.
61. Yang HI, Yuen MF, Chan HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011;12:568-74.
62. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-74.
63. Loomba R, Liu J, Yang HI, et al. Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma. Clin Gastroenterol Hepatol 2013;11:1636-45.e1.
64. Chayanupatkul M, Omino R, Mittal S, et al. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. J Hepatol 2017;66:355-62.
65. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991;350:427-8.
66. AFEF. 2020. Available from: https://afef.asso.fr/wp-content/uploads/2020/07/DNI-VERSION-FINALE-RECO-2020.pdf. [Last accessed on 17 Mar 2021].
67. Wong VW, Janssen HL. Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection? J Hepatol 2015;63:722-32.
68. Trinchet JC, Chaffaut C, Bourcier V, et al. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire (GRETCH). Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011;54:1987-97.
69. Costentin CE, Layese R, Bourcier V, et al. ANRS CO12 CirVir Group. Compliance with hepatocellular carcinoma surveillance guidelines associated with increased lead-time adjusted survival of patients with compensated viral cirrhosis: A Multi-Center Cohort Study. Gastroenterology 2018;155:431-42.e10.
70. WHO. 2020. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf. [Last accessed on 17 Mar 2021].
71. Yang JD, Mohamed EA, Aziz AO, et al. Africa Network for Gastrointestinal and Liver Diseases. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. Lancet Gastroenterol Hepatol 2017;2:103-111.
72. Ayoub HH, Chemaitelly H, Kouyoumjian SP, Abu-Raddad LJ. Characterizing the historical role of parenteral antischistosomal therapy in hepatitis C virus transmission in Egypt. Int J Epidemiol 2020;49:798-809.
73. Okeke E, Davwar PM, Roberts L, et al. Epidemiology of Liver Cancer in Africa: Current and Future Trends. Semin Liver Dis 2020;40:111-23.
75. Yang JD, Gyedu A, Afihene MY, et al. Africa Network for Gastrointestinal and Liver Diseases. Hepatocellular carcinoma occurs at an earlier age in Africans, particularly in association with chronic hepatitis B. Am J Gastroenterol 2015;110:1629-31.
76. Sultan A, Anugwom CM, Wondifraw Z, Braimoh GA, Bane A, Debes JD. Single center analysis of therapy and outcomes of hepatocellular carcinoma in Sub-Saharan Africa. Expert Rev Gastroenterol Hepatol 2020;14:1007-11.
77. Aby ES, Sultan A, Sultan A, Wondifraw Z, Debes JD. Outcomes of sorafenib therapy in advanced hepatocellular carcinoma in a single center in Ethiopia. Eur J Gastroenterol Hepatol 2020;32:1407-8.
78. Breakwell L, Tevi-Benissan C, Childs L, Childs L, Tohme R. The status of hepatitis B control in the African region. Pan Afr Med J 2017;27:17.
79. Spearman CW, Sonderup MW. Preventing hepatitis B and hepatocellular carcinoma in South Africa: The case for a birth-dose vaccine. S Afr Med J 2014;104:610-2.
80. Wilson P, Parr JB, Jhaveri R, Meshnick SR. Call to action: Prevention of mother-to-child transmission of hepatitis B in Africa. J Infect Dis 2018;217:1180-3.
81. Dooso Oloo R, Okoth S, Wachira P, et al. Genetic Profiling of Aspergillus Isolates with Varying Aflatoxin Production Potential from Different Maize-Growing Regions of Kenya. Toxins (Basel) 2019;11:467.
82. Szymańska K, Lesi OA, Kirk GD, et al. Ser-249TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in the Gambia, West Africa. Int J Cancer 2004;110:374-9.
83. Ryder RW, Whittle HC, Sanneh AB, Ajdukiewicz AB, Tulloch S, Tulloch S. Persistent hepatitis B virus infection and hepatoma in The Gambia, west Africa. A case-control study of 140 adults and their 603 family contacts. Am J Epidemiol 1992;136:1122-31.
84. Wills W, Saimot G, Brochard C, et al. Hepatitis B surface antigen (Australia antigen) in mosquitoes collected in Senegal, West Africa. Am J Trop Med Hyg 1976;25:186-90.
85. Maponga TG, Glashoff RH, Glashoff RH, et al. Hepatitis B virus-associated hepatocellular carcinoma in South Africa in the era of HIV. BMC Gastroenterol 2020;20:226.
86. Lemoine M, Thursz MR. Battlefield against hepatitis B infection and HCC in Africa. J Hepatol 2017;66:645-54.
87. Stewart KA, Navarro SM, Navarro SM, et al. Trends in ultrasound use in low and middle income countries: A systematic review. Int J MCH AIDS 2020;9:103-20.
88. Shah S, Abbas G, Hanif M, et al. Increased burden of disease and role of health economics: Asia-pacific region. Expert Rev Pharmacoecon Outcomes Res 2019;19:517-28.
89. Wong TW, Wong AH. A review of statutory medical examinations in Asian-Pacific countries. Am J Ind Med 2011;54:78-88.
90. Ashtari S, Pourhoseingholi MA, Sharifian A, Zali MR. Hepatocellular carcinoma in Asia: Prevention strategy and planning. World J Hepatol 2015;7:1708-17.
91. Bertuccio P, Turati F, Turati F, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol 2017;67:302-9.
92. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
93. Liaw YF. Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol 2009;51:403-10.
94. Liu Y, Wu F. Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect 2010;118:818-24.
95. Jafri W, Kamran M. Hepatocellular carcinoma in Asia: A challenging situation. Euroasian J Hepatogastroenterol 2019;9:27-33.
97. Raihan R, Akbar SMF, Al Mahtab M, et al. Genomic analysis of Hepatitis B virus and its association with disease manifestations in Bangladesh. PLoS One 2019;14:e0218744.
98. Chuon C, Takahashi K, Matsuo J, et al. High possibility of hepatocarcinogenesis in HBV genotype C1 infected Cambodians is indicated by 340 HBV C1 full-genomes analysis from GenBank. Sci Rep 2019;9:12186.
99. Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016;10:1-98.
100. Howell J, Pedrana A, Cowie BC, et al. Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030. J Gastroenterol Hepatol 2019;34:40-8.
102. MacLachlan J, Allard N, Carville K, Haynes K, Cowie B. Mapping progress in chronic hepatitis B: geographic variation in prevalence, diagnosis, monitoring and treatment, 2013-15. Aust N Z J Public Health 2018;42:62-8.
103. Hong TP, Gow P, Fink M, et al. Novel population-based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed. Hepatology 2016;63:1205-12.
104. Mules T, Gane E, Lithgow O, Bartlett A, McCall J. Hepatitis B virus-related hepatocellular carcinoma presenting at an advanced stage: is it preventable? N Z Med J 2018;131:27-35.
105. Jackson K, Tekoaua R, Holgate, et al. Hepatitis B and D in the Pacific Islands of Kiribati. J Clin Virol 2020;129:104527.
106. MacLachlan JH, Cowie BC. Liver cancer is the fastest increasing cause of cancer death in Australians. Med J Aus 2012;19:492-3.
